Here are some commonly asked questions about molecular diagnostic testing at NSO.
No! We accept samples from patients of all ages and a number of indications. Diagnostic testing can be requested for any individual who presents with symptoms of these diseases. Carrier testing can also be requested (including familial variant testing and full gene sequencing for reproductive partners). We also offer prenatal testing (see question below).
If your request is urgent, please indicate how a shorter TAT will change patient management by selecting the appropriate reason on the requisition. Accepted reasons to expedite testing include the following: • Ongoing pregnancy and result is needed for decision making within 6 weeks • Positive newborn screens where molecular results are essential for treatment decisions • Expedited results will directly impact management decisions We aim to report as soon as possible and to have all reports issued within the above times. Feel free to contact us for a status update on a report or if clinical circumstances change and issuing a report sooner is needed; we will accommodate to the best of our ability.
Exome data can be requested for further analyses/interpretation in a research setting if a signed research consent has been obtained. If you are interested in requesting this, please contact us for further details.
Prenatal testing is available when familial variants have been previously identified or there is clinical suspicion for the disease. Please contact us prior to sending a prenatal sample.
For prenatal testing requests, NSO requires that MCC studies be completed. As this is not yet available at NSO, we currently require that this testing be arranged externally and that a copy of these results be provided before a report can be issued. Please note that the MCC studies must be done on the specimen that is being shipped to us for analysis (for example, if we are receiving DNA extracted from cultured amniocytes, then MCC studies performed on direct amniotic fluid would not be acceptable).
We require extracted DNA for prenatal requests. We do not accept direct amniotic fluid, chorionic villus samples, or uncultured/cultured cells. Please make sure that a back-up culture is set up in case another sample is needed to complete the testing.
Deletion/duplication testing via MLPA is available for CYP21A2, PAH and ACADM. Copy Number Variation (CNV) analysis is not routinely performed; we do however manually inspect NGS data for possible CNVs by assessing read depth variation in genes with one clinically significant variant. While we are not able to assess the sensitivity of this method, we have successfully identified many CNVs with this approach. Our capture methodology along with NGS does not detect large deletions, insertions, chromosomal abnormalities or large rearrangements. We continue to refine our approaches to CNV analysis and updates will be posted here. Please feel free to contact us if you have questions about coverage for possible CNVs in any genes, generally or in the context of a specific patient.
If a variant of uncertain significance is identified, is it possible to have the interpretation reevaluated at a later date?
Reinterpretation of a variant is available upon request.
Please use our molecular requisition to submit these requests and include a copy of the NSO report previously issued.
I have requested for a variant to be reinterpreted. How will the variant’s updated interpretation be communicated?
A new report will be issued for all requests, even if the interpretation remains unchanged.